Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is a promising company with a strong focus on developing and providing bioprocessing products and services for the growing CGT industry. With a majority of its revenue coming from CryoStor, the company has a stable and diverse revenue stream. The recent acquisition offer by RGEN offers a fair reflection of the company's biopreservation franchise and provides potential for future growth through RGEN's stock performance. Overall, the company appears to have a balanced risk/reward profile and is a solid investment opportunity.

Bears say

BioLife Solutions is a life sciences company that is facing risks such as potential delays in the announced acquisition, weakness in Repligen shares, and potential regulatory obstacles. The company's recent acquisition by Repligen is a logical step in simplifying its portfolio and expanding its reach, but it remains to be seen if the benefits will outweigh any potential risks in the long term. Moreover, while BioLife's products have a strong presence in the market and complement Repligen's offerings, there are still potential challenges in securing additional customers and fluctuating sales in emerging markets that could impact the company's growth and financials.

BioLife Solutions (BLFS) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Hold based on their latest research and market trends.

According to 5 analysts, BioLife Solutions (BLFS) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.